Back to top
more

Genomic Health, Inc. (GHDX)

(Delayed Data from NSDQ)

$67.55 USD

67.55
321,603

+1.67 (2.53%)

Updated May 3, 2019 04:00 PM ET

After-Market: $67.63 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks News

Zacks.com featured highlights: Cabot Oil & Gas, Cardiovascular Systems, Fortress Transportation and Infrastructure, Genomic Health and Par Pacific Holdings

Zacks.com featured highlights: Cabot Oil & Gas, Cardiovascular Systems, Fortress Transportation and Infrastructure, Genomic Health and Par Pacific Holdings

    Kevin Matras headshot

    A Company's First Profit Can Mean Big Profits to Investors

    Kevin Matras screens for companies showing their 'first profit' and explains why they are ones to watch. Highlighted stocks include COG, CSII, FTAI, GHDX and PARR.

      Genomic Health's GPS Predicts Metastatic Prostate Cancer

      Genomic Health, Inc. (GHDX), a global cancer company, recently unveiled positive results regarding Oncotype DX Genomic Prostate Score (GPS).

        Genomic Health's Cancer Test Business Strong, Expenses High

        On Mar 20, we issued an updated research report on Redwood City, CA-based Genomic Health Inc. (GHDX), a leading global cancer company with a focus on advanced molecular diagnostics.

          Genomic Health (GHDX) Up 2.1% Since Earnings Report: Can It Continue?

          Genomic Health (GHDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

            Genomic Health's Breast Recurrence Test Data Encouraging

            Genomic Health, Inc. (GHDX), a leading molecular diagnostics company, recently presented results from 15 Oncotype DX Breast Recurrence Score studies.

              Genomic Health (GHDX) Earnings Surpass Estimates in Q4

              Genomic Health, Inc. (GHDX) reported fourth-quarter 2016 earnings per share of 4 cents, reflecting an improvement from the year-ago quarter's loss figure of 8 cents.

                Genomic Health Posts Impressive Data for Oncotype DX Test

                Genomic Health Inc. (GHDX) recently unveiled positive findings of its Oncotype DX test in individualizing breast cancer treatment decisions for patients at various stages of the disease.

                  Will Endopredict Win Myriad's (MYGN) Genomic Testing War?

                  Myriad Genetics (MYGN) released favorable study results demonstrating the superiority of EndoPredict test over Oncotype Dx on long-term recurrence of breast cancer.

                    Genomic Health: Cancer Test Business Strong, Q3 Dismal

                    On Dec 6, we issued an updated research report on Redwood City, CA-based Genomic Health Inc. (GHDX).